Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/01/19
End: 04/30/20
Due: 04/30/21
Phase: N/A
Priority: Normal
Start: 10/11/22
End: 06/10/23
Due: 06/10/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines | NCT04281095 | ATGC Co., Ltd. | user2@example.com | None | 2019-11-01 | 2020-04-30 | 2021-04-30 | - | - | 2025-07-14 |
| Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines | NCT05623410 | ATGC Co., Ltd. | user2@example.com | None | 2022-10-11 | 2023-06-10 | 2024-06-10 | - | - | 2025-07-14 |